健脾补肾方联合干扰素治疗HBeAg阳性慢性乙型肝炎临床研究  

Clinical Study on Jianpi Bushen Prescription Combined with Interferon for HBeAg-positive Chronic Hepatitis B

作　　者：陈亮[1] 姜小艳[2] 贺劲松[1] 占伯林[1] 赖姿娜[1] 周大桥[1] 李群[1] 钟伟超 彭得倜 CHEN Liang;JIANG Xiaoyan;HE Jingsong;ZHAN Bolin;LAI Zina;ZHOU Daqiao;LI Qun;ZHONG Weichao;PENG Deti

机构地区：[1]深圳市中医院,广东深圳518033 [2]广州中医药大学附属第四临床医学院,广东深圳518033

出　　处：《新中医》2019年第7期176-179,共4页New Chinese Medicine

基　　金：广东省中医药局项目(20152052)

摘　　要：目的:观察健脾补肾方联合干扰素治疗对乙型肝炎e抗原(HBeAg)阳性慢性乙型肝炎(CHB)患者肝功能及血清Th1型细胞因子水平的影响。方法:选取63例HBeAg阳性CHB患者,最终60例患者纳入分析,随机分为治疗组28例和对照组32例。对照组给予聚乙二醇干扰素α-2 a注射液皮下注射,治疗组在对照组治疗基础上加服健脾补肾方。比较2组治疗前后的肝功能指标包括谷丙转氨酶(ALT)、谷草转氨酶(AST)、血清总胆红素(TBi)l及血清Th1型细胞因子白细胞介素-2 (IL-2)、γ-干扰素(IFN-γ)水平的变化。结果:治疗12、24、36、48周,2组ALT及AST水平均较治疗前下降(P <0.05);治疗36、48周,治疗组ALT及AST水平均低于同期对照组(P <0.05)。治疗12、24、36、48周,2组TBil水平与治疗前比较,差异均无统计学意义(P> 0.05);各治疗时间点TBil水平组间比较,差异均无统计学意义(P> 0.05)。治疗12、24、36、48周,2组IL-2水平均较治疗前上升(P <0.05);治疗24、36、48周,治疗组IL-2水平均高于同期对照组(P <0.05)。2组治疗36、48周及治疗组治疗24周时IFN-γ水平均较治疗前升高(P <0.05);治疗36、48周,治疗组IFN-γ水平均高于同期对照组(P <0.05)。结论:健脾补肾方能改善HBeAg阳性CHB患者的肝功能指标及Th1型细胞因子水平。Objective:To observe the effect of Jianpi Bushen prescription combined with interferon on the liver function indexes and levels of serum Th1 cytokines of patients with hepatitis Be antigen(HBeAg)-positive chronic hepatitis B(CHB).Methods: 63 cases of patients with HBeAg-positive CHB were selected, of whom 60 cases were enrolled in the final analysis,and divided them into two groups randomly,28 cases in the treatment group and 32 cases in the control group. The control group was given peginterferon α-2 a solution via subcutaneous injection, while the treatment group additionally received the oral administration of Jianpi Bushen prescription. Compared the changes of liver function indexes [alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBil)] and levels of serum Th1 cytokines including IL-2 and IFN-γ in both groups before and after treatment. Results:During treatment for 12,24,36 and 48 weeks,the levels of ALT and AST in both groups were lower than those before treatment(P < 0.05);during treatment for 36 and 48 weeks,the levels of ALT and AST in the treatment group were both lower than those in the control group in the same period(P < 0.05).During treatment for 12,24,36 and 48 weeks,comparing the levels of TBil in both groups with those before treatment,there were no significant differences being found(P > 0.05);comparing the levels of TBil in-between the two groups in each time point,there were no significant differences being found(P > 0.05). During treatment for 12,24,36 and 48 weeks,the levels of IL-2 in both groups were higher than those before treatment(P < 0.05);during treatment for 24,36 and 48 weeks,the levels of IL-2 in the treatment group were higher than those in the control group in the same period(P < 0.05). During treatment for 36 and 48 weeks in both groups and during treatment for 24 weeks in the treatment group,the levels of IFN-γ were higher than those before treatment(P < 0.05);during treatment for 36 and 48 weeks, the levels of IFN-γ in the treatment group wer

关 键 词：慢性乙型肝炎(CHB) 乙型肝炎e抗原(HBeAg) 中西医结合疗法 健脾补肾方 干扰素 肝功能 细胞因子 

分 类 号：R512.62[医药卫生—内科学]